Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             116 results found
no title author magazine year volume issue page(s) type
1 Abstracts of the 51st A.I.S.F. – Italian Association for the Study of the Liver – Annual Meeting 2018 Rome, February 22nd–23rd, 2018: THANKS to experts 2018
 50 1S p. 62
 article
2 Acquisition of stem-like features in human cholangiocarcinoma is associated with an oxidative glucose metabolism Raggi, C.
 2018
 50 1S p. 43
 article
3 Adherence to EASL antibiotic treatment recommendations improves the outcomes of patients with cirrhosis and bacterial infections. Results from the ICA “Global Study” Piano, S.
 2018
 50 1S p. 23-24
 article
4 A spleen stiffness measurement-based model for the recognition of high risk varices: Baveno VI criteria and beyond Colecchia, A.
 2018
 50 1S p. 33-34
 article
5 Assessing the risk of de novo neoplasms after liver transplantation: Role of pre-transplant hepatocellular carcinoma Shalaby, S.
 2018
 50 1S p. 35
 article
6 A worldwide cross-ethnic study of quality of life in patients with PBC: Attitude or latitude? Carbone, M.
 2018
 50 1S p. 26
 article
7 Bacterial infections with and without acute-on-chronic liver failure in patients with cirrhosis and acute decompensation: Risk factors and outcome Bartoletti, M.
 2018
 50 1S p. 10
 article
8 Basal values and on treatment decline of hepatitis B core-related antigen are predictive of response to interferon therapy in patients with chronic hepatitis D Olivero, A.
 2018
 50 1S p. 60
 article
9 Baseline clinical features but not TLL1 variants predicts HCC onset in Caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years Loglio, A.
 2018
 50 1S p. 51
 article
10 Berberis aristata, Elaeis guineensis and Coffea canephora extracts modulates the microRNA-122 expression and improves hepatic steatosis in mice fed high fat diet Lembo, V.
 2018
 50 1S p. 17
 article
11 Bile acid composition modulates insulin resistance in non-diabetic patients with NAFLD Rosso, C.
 2018
 50 1S p. 17
 article
12 Bridging therapies are not detrimental in patients with hepatocellular cancer waiting for liver transplant: A propensity score analysis Lai, Q.
 2018
 50 1S p. 7-8
 article
13 Changes of AFP and PIVKA-II levels during DAA treatment and their predictive value for early diagnosis of HCC in HCV cirrhotic patients with SVR to DAA treatment Sangiovanni, A.
 2018
 50 1S p. 49
 article
14 Changes of indications for liver transplantation in the era of direct acting antiviral therapy in Europe Perricone, G.
 2018
 50 1S p. 9
 article
15 Characterization of HBV integration landscape in tumor and non-tumor liver tissues by a high-throughput viral integration detection method D’Aliberti, D.
 2018
 50 1S p. 29
 article
16 Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy Barbaliscia, S.
 2018
 50 1S p. 46-47
 article
17 Clinical significance of time related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma Ricco, G.
 2018
 50 1S p. 14-15
 article
18 Combination of HBV serological markers can predict the burden and productivity of intrahepatic HBV reservoir and disease progression in HBeAg-negative chronic hepatitis B infection Salpini, R.
 2018
 50 1S p. 13
 article
19 Dexamethasone reduces cholestasis-associated oxidative stress and inflammation in bile-duct ligated rats via CAR activation Gabbia, D.
 2018
 50 1S p. 6-7
 article
20 Direct-acting antiviral therapy immediately after liver transplant in naïve or NS5A-relapser recipients Martini, S.
 2018
 50 1S p. 60
 article
21 Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort Calvaruso, V.
 2018
 50 1S p. 1-2
 article
22 Durable response in the markers of cholestasis through 36 months of open-label extension with obeticholic acid in Italian patients with primary biliary cholangitis Andreone, P.
 2018
 50 1S p. 26
 article
23 Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: Safety and survival Invernizzi, F.
 2018
 50 1S p. 49
 article
24 Editorial Board 2018
 50 1S p. i
 article
25 Effectiveness and safety of DAA treatment for recurrent hepatitis C after liver transplantation: The NAVIGATOR Lombardia-Veneto network Invernizzi, F.
 2018
 50 1S p. 32
 article
26 Endoscopic radiofrequency ablation for the treatment of Gastric Antral Vascular Ectasia in cirrhotic patients: A bi-centric clinical and economical cost-effective analysis Senzolo, M.
 2018
 50 1S p. 2
 article
27 Epidemiology, predictors and outcomes of multi drug resistant (MDR) bacterial infections in patients with cirrhosis across the world. Final results of the “Global study” Piano, S.
 2018
 50 1S p. 2-3
 article
28 Establishment of expanding 3D-organoids cultures from human fetal biliary tree stem cells (hBTSCs) as a potential tool for regenerative medicine and disease modeling Safarikia, S.
 2018
 50 1S p. 25
 article
29 Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study Group Degasperi, E.
 2018
 50 1S p. 52
 article
30 Excellent effectiveness of direct-acting antivirals for HCV treatment in patients with cirrhosis: Analysis of 3345 patients from the Lombardia Network Degasperi, E.
 2018
 50 1S p. 38
 article
31 Excellent 5-years survival for HBV cirrhotic patients developing a hepatocellular carcinoma during long-term analogs treatment Iavarone, M.
 2018
 50 1S p. 11
 article
32 Extracellular signal-regulated kinase 5 (ERK5) regulates growth, migration and invasion of cholangiocarcinoma (CCA) cells Gentilini, A.
 2018
 50 1S p. 43
 article
33 Fatty liver susceptibility to preservation injury using static cold storage versus dynamic machine perfusion Siciliano, V.
 2018
 50 1S p. 8-9
 article
34 Fibroscan liver stiffness (LMS) and controlled attenuation parameter (CAP) in the evaluation of cardiovascular risk assessment in patients with NAFLD Lombardi, R.
 2018
 50 1S p. 37
 article
35 Filamin A expression predicts early recurrence of hepatocellular carcinoma after hepatectomy Donadon, M.
 2018
 50 1S p. 38-39
 article
36 Forecasting liver disease burden Robbins, S.
 2018
 50 1S p. 10-11
 article
37 Functional characterization of a novel genetic variant predisposing to hepatocellular carcinoma development in nonalcoholic fatty liver disease Baselli, G.A.
 2018
 50 1S p. 16
 article
38 Galectin-3+ cells in the liver associate with tissue damage in children with NAFLD Panera, N.
 2018
 50 1S p. 53
 article
39 Gender dimorphism in fibrosis dynamics in a murine model of chronic hepatic injury Crescenzi, M.
 2018
 50 1S p. 4-5
 article
40 Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: A pilot study Di Costanzo, G.G.
 2018
 50 1S p. 27
 article
41 HBV reservoir and enhanced cccDNA transcriptional activity in HBeAg negative chronic hepatitis B Colagrossi, L.
 2018
 50 1S p. 27
 article
42 HCC recurrence after DAA treatment in HCV patients Guarino, M.
 2018
 50 1S p. 50
 article
43 HCV clearance and pro-thrombotic shift in advanced liver disease Biliotti, E.
 2018
 50 1S p. 52-53
 article
44 HCV eradication by DAA improves glucose tolerance and reduces post-load insulin resistance in cirrhotic patients with genotype 1 Salomone, F.
 2018
 50 1S p. 20-21
 article
45 HCV-FiS (HEpatitis C Virus Finger-stick Study): HCV RNA point-of-care testing by GeneXpert in the setting of DAA therapy Bronte, F.
 2018
 50 1S p. 58
 article
46 Health-economic evaluation of different organizational models to manage the Hepatitis C patient journey Fagiuoli, S.
 2018
 50 1S p. 31
 article
47 Hepatic ischemic injury decreases using negative allosteric modulators of metabotropic glutamate receptor subtype 5 Berardo, C.
 2018
 50 1S p. 24
 article
48 Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis/compensated cirrhosis Petta, S.
 2018
 50 1S p. 31
 article
49 IFN-free DAA treatment of cirrhotic HCV patients with or without history of HCC: A multicenter prospective trial in Italy Sangiovanni, A.
 2018
 50 1S p. 12-13
 article
50 IL28 polymorphism and HCC after DAAs for chronic hepatitis C Simili, A.
 2018
 50 1S p. 32-33
 article
51 Immune inflammation indicators and ALBI score to predict occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals Gardini, A.C.
 2018
 50 1S p. 50-51
 article
52 Impact of Neuromedin-B receptor variants on iron overload disorders Rametta, R.
 2018
 50 1S p. 25
 article
53 Impact of Proprotein Convertase Subtilisin/Kexin Type 7 genetic variation in patients with non-alcoholic fatty liver disease Dongiovanni, P.
 2018
 50 1S p. 19
 article
54 Impaired renal function but high sustained virological response (SVR) rates in hepatitis C virus (HCV) elderly treated with direct-acting antivirals (DAA): A report from the Lombardy Network D’Ambrosio, R.
 2018
 50 1S p. 13-14
 article
55 Incidence and outcome of portal vein thrombosis in HCV cirrhotic patients treated with direct-acting antivirals: A single-center prospective 3-year study Degasperi, E.
 2018
 50 1S p. 30
 article
56 Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: A single-center prospective 3-year study D’Ambrosio, R.
 2018
 50 1S p. 36
 article
57 Incidence, prevalence and mortality of Primary Sclerosing Cholangitis (PSC) in Italy: A population-based study Carbone, M.
 2018
 50 1S p. 6
 article
58 Incomplete normalization of transaminases at 18 months is the most important predictor for failure of biochemical response in autoimmune hepatitis Gerussi, A.
 2018
 50 1S p. 29
 article
59 Influence of DAA treatment on waitlisting and transplant rate for HCV related disease: Preliminary results of a single center experience Iegri, C.
 2018
 50 1S p. 44
 article
60 Insulin resistance improvement after effective Hepatitis C virus eradication and its role on the onset of complications of advanced liver disease Bortoluzzi, I.
 2018
 50 1S p. 48
 article
61 Is stiffness reliable for the detection of liver fibrosis in HCV patients treated with direct acting antiviral drugs (DAAs)? A prospective cohort study Gaia, S.
 2018
 50 1S p. 36
 article
62 Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis Masetti, C.
 2018
 50 1S p. 4
 article
63 Liver function tests do not predict liver damage in diabetes. Analysis of liver steatosis and fibrosis by transient elastography in routine diabetes care Lombardi, R.
 2018
 50 1S p. 57
 article
64 Liver stiffness based model (LSPS) predicts measured portal hypertension (mPH), esophageal varices (EVs) and HCC in patients treated and responsive to DAA for HBV and HCV-related cirrhosis Tucci, A.
 2018
 50 1S p. 51
 article
65 Liver stiffness predicts the development of portal hypertension related complications in advanced chronic liver disease Mulazzani, L.
 2018
 50 1S p. 48
 article
66 Liver transplant organ allocation; preliminary results using the ISO score system Bertacco, A.
 2018
 50 1S p. 54
 article
67 Loss of hepatic RuvBL1 accelerates DEN-induced carcinogenesis due to chronic liver damage and regeneration Materozzi, M.
 2018
 50 1S p. 15-16
 article
68 Low levels of squamous cell carcinoma antigen–IgM complexes in serum are predictors of better survival in patients with liver cirrhosis Cagnin, M.
 2018
 50 1S p. 42
 article
69 Lymphoid infiltrate predicts prognosis of mass-forming intrahepatic cholangiocarcinoma undergoing complete liver resection Vigano, L.
 2018
 50 1S p. 8
 article
70 Metabolomics in the progression of non alcoholic fatty liver disease Troisi, J.
 2018
 50 1S p. 18
 article
71 Microwave ablation and salvage transplantation for patients with hepatocellular carcinoma Bertacco, A.
 2018
 50 1S p. 44-45
 article
72 Modulation of the NLRP3 inflammasome pathway mediates the anti-inflammatory action of indoleamine dioxygenase in experimental NASH Vivoli, E.
 2018
 50 1S p. 16
 article
73 Monofocal hepatocellular carcinoma (HCC): Is diameter so important? Analysis on the Italian Liver Cancer (ITA.LI.CA) database between BCLC algorithm and Milan criteria Peserico, G.
 2018
 50 1S p. 53
 article
74 Multimodal and sequential treatment for hepatocellular carcinoma: How “real-life” complies with international recommendations Triolo, M.
 2018
 50 1S p. 45
 article
75 National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing Ruggiero, T.
 2018
 50 1S p. 55-56
 article
76 Natural killer cell trafficking dysfunction in hepatocellular carcinoma Missale, G.
 2018
 50 1S p. 34
 article
77 Non-invasive evaluation of change in liver fibrosis after viral eradication in patients with HCV related cirrhosis Carrara, R.
 2018
 50 1S p. 61
 article
78 Non-invasive measurement of HVPG using graph analysis based on dynamic contrast-enhanced ultrasound with ESAOTE MyLab: The CLEVER Study Piscaglia, F.
 2018
 50 1S p. 33
 article
79 Noninvasive prediction of esophageal varices by liver stiffness measurement and platelet values in patients with liver cirrhosis due to nonalcoholic fatty liver disease: A multicenter cross-sectional study Petta, S.
 2018
 50 1S p. 3-4
 article
80 Oleuropein and copper: New perspectives against liver disease Balsano, C.
 2018
 50 1S p. 56
 article
81 Outbreak of Acute Hepatitis A involving young men in Lombardy region, Italy: Risk factors, clinical and virological characteristics Iavarone, M.
 2018
 50 1S p. 5
 article
82 Pathobiological and radiomic approach for hepatocellular carcinoma subclassification Vasuri, F.
 2018
 50 1S p. 15
 article
83 Pathological characteristics and early post-hepatic-resection outcome of patients with hepatocellular carcinoma occurred after hepatitis C treatment with new direct-acting antivirals: A multicenter cohort study Vitale, A.
 2018
 50 1S p. 9-10
 article
84 Pattern of hepatocarcinoma recurrence in cirrhosis: The role of anatomic and parenchyma-sparing resection. A propensity score analysis Famularo, S.
 2018
 50 1S p. 39
 article
85 Predictors of hepatocellular recurrence after liver transplant in Hepatitis C patients: A ten-years single center cohort Iavarone, M.
 2018
 50 1S p. 54
 article
86 Pre-treatment risk stratification in primary biliary cholangitis: A predictive model to guide first-line combination therapy Carbone, M.
 2018
 50 1S p. 21-22
 article
87 Primary Biliary Cholangitis (PBC): The emotional perception of the disease journey from a patient's perspective Alvaro, D.
 2018
 50 1S p. 57
 article
88 Primary biliary cholangitis (PBC): The patient journey to diagnosis and through the disease Floreani, A.
 2018
 50 1S p. 42-43
 article
89 Prognostic role of BAP1 and PBRM1 expression in intrahepatic cholangiocarcinoma Sarcognato, S.
 2018
 50 1S p. 39
 article
90 Progressive reduction of blood lysosomal acid lipase activity according to stage of adult chronic liver disease and altered enzymatic cellular distribution in cirrhosis Mignini, I.
 2018
 50 1S p. 37
 article
91 Reasons for recipient ineligibility for liver transplantation Biolato, M.
 2018
 50 1S p. 7
 article
92 Right timing for transient elastography lead the right follow up after HCV treatment Scribano, L.
 2018
 50 1S p. 56
 article
93 Risk and outcome of hepatitis B virus (HBV) reactivation during chronic hepatitis C treatment with direct-acting antivirals (DAAs) in patients with HCV-related advanced fibrosis: A single-center experience D’Ambrosio, R.
 2018
 50 1S p. 41
 article
94 Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen levels in the natural history of chronic HBV infection Caviglia, G.P.
 2018
 50 1S p. 12
 article
95 Role of nutritional intake on clinical presentation of lean and overweight NAFLD Pisano, G.
 2018
 50 1S p. 59
 article
96 Role of rare pathogenic mutations in the development of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease Pelusi, S.
 2018
 50 1S p. 28
 article
97 Role of SERPINB3 like serological and molecular biomarker into NASH development and progression Maier, S.
 2018
 50 1S p. 18
 article
98 Role of the protein tyrosine kinase Mer (MerTK) in the cross-talk between macrophages and hepatic stellate cells Pastore, M.
 2018
 50 1S p. 28-29
 article
99 Safety and effectiveness of DAA treatment and clinical outcomes of HCV liver transplanted patients with recurrent hepatitis C infection: A single center 3-year study from Italy Invernizzi, F.
 2018
 50 1S p. 61
 article
100 Sarcopenia predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib Antonelli, G.
 2018
 50 1S p. 14
 article
101 Screening of esophagogastric varices: Performance of the “Expanded Baveno VI criteria” and the “platelet 150/MELD 6” strategy in all etiology compensated advanced chronic liver disease Tosetti, G.
 2018
 50 1S p. 59
 article
102 Serum and bile squamous cell carcinoma antigen detection: A new prognostic marker in patients with perihilar cholangiocarcinoma Gringeri, E.
 2018
 50 1S p. 40
 article
103 Shear wave elastography to assess spleen stiffness: Its feasibility and reproducibility in patients with chronic liver disease and its utility in the prediction of portal hypertension Conti, C.B.
 2018
 50 1S p. 35
 article
104 Specific human cholangiocarcinoma (CCA) subpopulations of cancer stem cells (CSCs) express DoubleCortin-Like Kinase 1 (DCLK1) and DCLK1 inhibition induces anti-cancer effects Nevi, L.
 2018
 50 1S p. 5-6
 article
105 SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with direct acting antivirals: A prospective multicenter Italian study Lleo, A.
 2018
 50 1S p. 34-35
 article
106 Technical assessment and reliability of controlled attenuation parameter (CAP) with M probe in NAFLD Salmi, A.
 2018
 50 1S p. 58
 article
107 Temporal trends of access to DAAs treatments for HCV in the Navigatore-Lombardia network: Evolution of AIFA criteria, DAA regimens and patient features Pasulo, L.
 2018
 50 1S p. 45-46
 article
108 The ALBI and p-ALBI grades predict survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization (TACE) Campani, C.
 2018
 50 1S p. 44
 article
109 The cancerogenic potential of primary human Cholangioracinoma cells is inhibited by Obeticholic Acid, a Farnesoid X Receptor (FXR) agonist Di Matteo, S.
 2018
 50 1S p. 22-23
 article
110 The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance Calvaruso, V.
 2018
 50 1S p. 20
 article
111 The exposure of primary cultures of human biliary tree stem/progenitor cells (hBTSCs) to different micro-environmental factors induces proliferation, epithelial-mesenchymal transition (EMT) and senescence, which are typical pathological features of human cholangiopathies Costantini, D.
 2018
 50 1S p. 30
 article
112 The inhibitory effect of ADM on hepatic NF-κB activation in 2D and 3D hepatic cell cultures De Martin, S.
 2018
 50 1S p. 24
 article
113 The protease-inhibitor SerpinB3 outlines a stem-like subset in human cholangiocarcinoma Raggi, C.
 2018
 50 1S p. 47-48
 article
114 Use of a new type of controlled expansion stent in the creation of Transjugular Intrahepastic Portosystemic Shunt for the treatment of severe portal hypertension. A single center experience with 1 year follow-up Petridis, I.
 2018
 50 1S p. 40
 article
115 Validation of the EASL 2017 HBV Clinical Practice Guidelines criteria for switching patients long-term treated with Tenofovir Difumarate to Entecavir or Tenofovir Alafenamide in a real-life setting Loglio, A.
 2018
 50 1S p. 55
 article
116 Video-laparoscopic MW ablation in a European high volume center: Safety and efficacy of 891 procedures Bertacco, A.
 2018
 50 1S p. 54-55
 article
                             116 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands